Yang JJ, et al. (2016) Activation of activator protein 2 alpha by aspirin alleviates atherosclerotic plaque growth and instability in vivo. Oncotarget 7, 52729-52739 27391154

This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.

Click on the protein name to open the protein page, and on the RSD number to open the site page.

Download

S219-p - AP-2 alpha (human) ▲

Modsite: CSVPGRLsLLSSTSK SwissProt Entrez-Gene Orthologous residues AP‑2 alpha (human): S219‑p, AP‑2 alpha iso2 (human): S213‑p, AP‑2 alpha (mouse): S219‑p, AP‑2 alpha (rat): S219‑p Characterization Methods used to characterize site in vivo:  immunoprecipitation, phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  leukocyte-blood, vascular smooth muscle cell ('muscle, smooth') Cellular systems studied:  primary cells Species studied:  human, mouse Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes aspirin increase Downstream Regulation Effect of modification (function):  activity, induced, molecular association, regulation Effect of modification (process):  transcription, induced Modification regulates interactions with:  Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays Induces co-immunoprecipitation Comments:  IkB-alpha expression